153 related articles for article (PubMed ID: 29656464)
1. Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors.
El-Sharkawy LY; El-Sakhawy RA; Abdel-Halim M; Lee K; Piazza GA; Ducho C; Hartmann RW; Abadi AH
Arch Pharm (Weinheim); 2018 May; 351(5):e1800018. PubMed ID: 29656464
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors.
Ahmed NS; Gary BD; Tinsley HN; Piazza GA; Laufer S; Abadi AH
Arch Pharm (Weinheim); 2011 Mar; 344(3):149-57. PubMed ID: 21384413
[TBL] [Abstract][Full Text] [Related]
3. Exploration of the 5-bromopyrimidin-4(3H)-ones as potent inhibitors of PDE5.
Gong X; Wang G; Ren J; Liu Z; Wang Z; Chen T; Yang X; Jiang X; Shen J; Jiang H; Aisa HA; Xu Y; Li J
Bioorg Med Chem Lett; 2013 Sep; 23(17):4944-7. PubMed ID: 23867165
[TBL] [Abstract][Full Text] [Related]
4. 8-(3-chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors.
Sakamoto T; Koga Y; Hikota M; Matsuki K; Mochida H; Kikkawa K; Fujishige K; Kotera J; Omori K; Morimoto H; Yamada K
Bioorg Med Chem Lett; 2015 Apr; 25(7):1431-5. PubMed ID: 25754491
[TBL] [Abstract][Full Text] [Related]
5. Design of novel β-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitors.
El-Gamil DS; Ahmed NS; Gary BD; Piazza GA; Engel M; Hartmann RW; Abadi AH
Arch Pharm (Weinheim); 2013 Jan; 346(1):23-33. PubMed ID: 23307609
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of novel 5-(3,4,5-trimethoxybenzoyl)-4-aminopyrimidine derivatives as potent and selective phosphodiesterase 5 inhibitors: scaffold hopping using a pseudo-ring by intramolecular hydrogen bond formation.
Sakamoto T; Koga Y; Hikota M; Matsuki K; Murakami M; Kikkawa K; Fujishige K; Kotera J; Omori K; Morimoto H; Yamada K
Bioorg Med Chem Lett; 2014 Nov; 24(22):5175-80. PubMed ID: 25442307
[TBL] [Abstract][Full Text] [Related]
8. Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
Kempson J; Pitts WJ; Barbosa J; Guo J; Omotoso O; Watson A; Stebbins K; Starling GC; Dodd JH; Barrish JC; Felix R; Fischer K
Bioorg Med Chem Lett; 2005 Apr; 15(7):1829-33. PubMed ID: 15780616
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of pyrazolo[3,4-d]pyrimidinone derivatives: Discovery of selective phosphodiesterase-5 inhibitors.
Shaaban MA; Elshaier YAMM; Hammad AH; Farag NA; Hassan Haredy H; AbdEl-Ghany AA; Mohamed KO
Bioorg Med Chem Lett; 2020 Aug; 30(16):127337. PubMed ID: 32631538
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors.
Barnes MJ; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Galvin FC; Gowers L; Haughan AF; Lowe C; Meissner JW; Montana JG; Morgan T; Picken CL; Watson RJ
Bioorg Med Chem Lett; 2001 Apr; 11(8):1081-3. PubMed ID: 11327595
[TBL] [Abstract][Full Text] [Related]
11. Microwave-assisted synthesis of potent PDE7 inhibitors containing a thienopyrimidin-4-amine scaffold.
Sánchez AI; Meneses R; Mínguez JM; Núñez A; Castillo RR; Filace F; Burgos C; Vaquero JJ; Álvarez-Builla J; Cortés-Cabrera A; Gago F; Terricabras E; Segarra V
Org Biomol Chem; 2014 Jun; 12(24):4233-42. PubMed ID: 24838636
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and properties of sildenafil isostere.
Su Z; Zhang Q; Zhao Q; Liu W; Zhao T; Wang H; Li J; Xu J
Arch Pharm (Weinheim); 2021 Oct; 354(10):e2100145. PubMed ID: 34131943
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of N
Pobsuk N; Paracha TU; Chaichamnong N; Salaloy N; Suphakun P; Hannongbua S; Choowongkomon K; Pekthong D; Chootip K; Ingkaninan K; Gleeson MP
Bioorg Med Chem Lett; 2019 Jan; 29(2):267-270. PubMed ID: 30509781
[TBL] [Abstract][Full Text] [Related]
14. Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease.
Kokkonen-Simon KM; Saberi A; Nakamura T; Ranek MJ; Zhu G; Bedja D; Kuhn M; Halushka MK; Lee DI; Kass DA
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089721
[TBL] [Abstract][Full Text] [Related]
15. Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors.
Abdel-Halim M; Tinsley H; Keeton AB; Weam M; Atta NH; Hammam MA; Hefnawy A; Hartmann RW; Engel M; Piazza GA; Abadi AH
Bioorg Chem; 2020 Nov; 104():104322. PubMed ID: 33142429
[TBL] [Abstract][Full Text] [Related]
16. A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors.
Ahmed NS; Gary BD; Piazza GA; Tinsley HN; Laufer S; Abadi AH
Med Chem; 2010 Nov; 6(6):374-87. PubMed ID: 21054274
[TBL] [Abstract][Full Text] [Related]
17. 1-(2-Ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors.
Tollefson MB; Acker BA; Jacobsen EJ; Hughes RO; Walker JK; Fox DN; Palmer MJ; Freeman SK; Yu Y; Bond BR
Bioorg Med Chem Lett; 2010 May; 20(10):3120-4. PubMed ID: 20443228
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
Sawant SD; Lakshma Reddy G; Dar MI; Srinivas M; Gupta G; Sahu PK; Mahajan P; Nargotra A; Singh S; Sharma SC; Tikoo M; Singh G; Vishwakarma RA; Syed SH
Bioorg Med Chem; 2015 May; 23(9):2121-8. PubMed ID: 25801159
[TBL] [Abstract][Full Text] [Related]
19. Diketopiperazine-Based, Flexible Tadalafil Analogues: Synthesis, Crystal Structures and Biological Activity Profile.
Mieczkowski A; Speina E; Trzybiński D; Winiewska-Szajewska M; Wińska P; Borsuk EM; Podsiadła-Białoskórska M; Przygodzki T; Drabikowski K; Stanczyk L; Zhukov I; Watala C; Woźniak K
Molecules; 2021 Feb; 26(4):. PubMed ID: 33546456
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
Reddy GL; Dar MI; Hudwekar AD; Mahajan P; Nargotra A; Baba AM; Nandi U; Wazir P; Singh G; Vishwakarma RA; Syed SH; Sawant SD
Bioorg Chem; 2019 Aug; 89():103022. PubMed ID: 31181491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
